<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cellular Neuroscience</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell. Neurosci.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1662-5102</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fncel.2025.1735225</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Early transcriptomic perturbations highlight the spinal cord as a key pathogenic region in spinocerebellar ataxia type 3</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Emerson</surname><given-names>Jacen</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3340549"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Nelthrope</surname><given-names>Brianna S.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Walker</surname><given-names>Emma A.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Mao</surname><given-names>Grace</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Shorrock</surname><given-names>Hannah K.</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1859918"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>McLoughlin</surname><given-names>Hayley S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1125213"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Neurology, University of Michigan</institution>, <city>Ann Arbor</city>, <state>MI</state>, <country country="us">United States</country></aff>
<aff id="aff2"><label>2</label><institution>Neuroscience Graduate Program, University of Michigan</institution>, <city>Ann Arbor</city>, <state>MI</state>, <country country="us">United States</country></aff>
<aff id="aff3"><label>3</label><institution>The RNA Institute and Department of Biological Sciences, College of Arts &#x0026; Sciences, University at Albany-SUNY</institution>, <city>Albany</city>, <state>NY</state>, <country country="us">United States</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Human Genetics, University of Michigan</institution>, <city>Ann Arbor</city>, <state>MI</state>, <country country="us">United States</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Hayley S. McLoughlin, <email xlink:href="mailto:hayleymc@umich.edu">hayleymc@umich.edu</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-14">
<day>14</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>19</volume>
<elocation-id>1735225</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>10</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>08</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Emerson, Nelthrope, Walker, Mao, Shorrock and McLoughlin.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Emerson, Nelthrope, Walker, Mao, Shorrock and McLoughlin</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-14">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disease caused by polyglutamine repeat expansion in the <italic>ATXN3</italic> gene. Despite the ubiquitous expression of ATXN3 throughout the body, SCA3 pathology is most pronounced in select, vulnerable central nervous system regions. Notably, spinal cord atrophy that is detectable by MRI emerges prior to ataxia symptom onset and progresses with disease severity. However, the pathogenic molecular signatures of the SCA3 spinal cord remain largely unexplored. Here, we present the first comprehensive analysis of the spinal cord transcriptome in SCA3 using both human and mouse model tissue. Our data reveal both early and progressive transcriptional dysregulation in the spinal cord, impacting key biological processes such as lipid metabolism, inflammation, cellular structure, and nucleic acid processing. Transcriptomic profiling of <italic>Atxn3</italic> knockout mouse spinal cord revealed only subtle transcriptional changes with little overlap to those in SCA3 knock-in mice, indicating that spinal cord pathology arising from gene expression changes are due to mutant ATXN3 toxic gain-of-function mechanisms, rather than ATXN3 loss-of-function. In addition, we observed aberrant RNA splicing changes in KI mice, particularly in oligodendrocyte signature genes. Collectively, these novel findings position the spinal cord as a primary and early site of SCA3 pathogenesis and underscore its potential both as a sensitive regional biomarker for disease progression and as a key target for therapeutic intervention.</p>
</abstract>
<kwd-group>
<kwd>alternative splicing</kwd>
<kwd>inflammation</kwd>
<kwd>oligodendrocyte</kwd>
<kwd>polyglutamine (polyQ) disease</kwd>
<kwd>SCA3</kwd>
<kwd>spinal cord</kwd>
<kwd>spinocerebellar ataxia</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the National Institutes of Health (R01-NS122751 and R01-NS140063 to HM; F31-NS145373 to JE; R01-NS135254 to HS).</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="68"/>
<page-count count="11"/>
<word-count count="8684"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Non-Neuronal Cells</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Spinocerebellar ataxia type 3 (SCA3) is a debilitating and invariably fatal neurodegenerative disorder, currently with no disease-modifying treatments (<xref ref-type="bibr" rid="ref49">Saute and Jardim, 2015</xref>; <xref ref-type="bibr" rid="ref35">Paulson et al., 2017</xref>; <xref ref-type="bibr" rid="ref6">Diallo et al., 2018</xref>; <xref ref-type="bibr" rid="ref28">Matos et al., 2019</xref>; <xref ref-type="bibr" rid="ref30">McLoughlin et al., 2020</xref>; <xref ref-type="bibr" rid="ref58">Stahl et al., 2024</xref>). SCA3 is caused by a CAG repeat expansion in the <italic>ATXN3</italic> gene, resulting in an abnormally long polyglutamine (polyQ) tract in the ATXN3 protein (<xref ref-type="bibr" rid="ref19">Kawaguchi et al., 1994</xref>; <xref ref-type="bibr" rid="ref61">Watanabe et al., 1996</xref>). This mutant, polyQ-expanded, ATXN3 pathologically accumulates within vulnerable cell types, although the precise regional mechanisms leading to cellular dysfunction remain unknown (<xref ref-type="bibr" rid="ref34">Paulson et al., 1997</xref>). Despite widespread expression of <italic>ATXN3</italic> throughout the body, neurodegeneration and protein accumulation in SCA3 predominantly impact select regions of the central nervous system (CNS), most notably the cerebellum and brainstem (<xref ref-type="bibr" rid="ref8">Durr et al., 1996</xref>; <xref ref-type="bibr" rid="ref45">R&#x00FC;b et al., 2002a</xref>, <xref ref-type="bibr" rid="ref46">2002b</xref>; <xref ref-type="bibr" rid="ref16">Guimar&#x00E3;es et al., 2013</xref>; <xref ref-type="bibr" rid="ref21">Koeppen, 2018</xref>; <xref ref-type="bibr" rid="ref30">McLoughlin et al., 2020</xref>; <xref ref-type="bibr" rid="ref14">Ferreira et al., 2024</xref>). These areas are well-recognized for their significant structural and functional decline in the disease, contributing to the classic motor and coordination deficits observed in patients (<xref ref-type="bibr" rid="ref16">Guimar&#x00E3;es et al., 2013</xref>; <xref ref-type="bibr" rid="ref18">Kang et al., 2014</xref>; <xref ref-type="bibr" rid="ref60">Wan et al., 2020</xref>; <xref ref-type="bibr" rid="ref14">Ferreira et al., 2024</xref>; <xref ref-type="bibr" rid="ref65">Ye et al., 2025</xref>). However, the spinal cord is also highly vulnerable in patients with SCA3, exhibiting substantial volumetric loss that can be detected by MRI prior to the onset of clinical symptoms and worsening as the disease advances (<xref ref-type="bibr" rid="ref27">Lukas et al., 2008</xref>; <xref ref-type="bibr" rid="ref12">Fahl et al., 2015</xref>; <xref ref-type="bibr" rid="ref42">Rezende et al., 2018</xref>, <xref ref-type="bibr" rid="ref41">2024</xref>; <xref ref-type="bibr" rid="ref11">Faber et al., 2021</xref>; <xref ref-type="bibr" rid="ref65">Ye et al., 2025</xref>). Considering the early and progressive nature of spinal cord atrophy in SCA3 patients, it is well-positioned as a regional biomarker of SCA3. Yet, despite its clear degeneration and likely contribution to SCA3 patient symptoms, the spinal cord has often been overlooked in preclinical studies and therapeutic development, which tend to focus on the cerebellum and brainstem. The specific molecular alterations underlying spinal cord vulnerability in SCA3 remain largely unexplored, underscoring the need for a more comprehensive understanding to drive the development of more effective, targeted interventions.</p>
<p>To elucidate the molecular mechanisms underlying SCA3 pathogenic signatures in the spinal cord, we employed a transcriptomic approach across human patient samples and mouse models. We performed RNA sequencing on spinal cord samples from human SCA3 patients and controls to characterize gene expression changes associated with advanced disease. To capture the onset and progression of transcriptomic alterations, we analyzed spinal cord tissue from an SCA3 knock-in (KI) mouse model, which carries one wild-type and one hyperexpanded (300 CAG) <italic>Atxn3</italic> allele (<xref ref-type="bibr" rid="ref53">Schuster et al., 2023</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>), at both symptomatic onset (24&#x202F;weeks) and end-stage disease (56&#x202F;weeks). To complement this, we performed transcriptomic profiling in 24-week-old <italic>Atxn3</italic> knockout (KO) mouse spinal cord tissue to help distinguish between ATXN3 loss-of-function and toxic gain-of-function effects in SCA3 mice. We applied weighted gene correlation network analysis (WGCNA) and gene ontology (GO) enrichment analyses to identify biological pathways impacted by disease. In addition, we examined changes in RNA splicing across all datasets to further characterize molecular disruptions associated with SCA3. Altogether, this approach allowed us to systematically interrogate the transcriptional landscape of the SCA3 spinal cord in both human and mouse models, providing a novel foundation for future investigations interrogating molecular mechanisms driving spinal cord disease pathology.</p>
</sec>
<sec sec-type="methods" id="sec2">
<label>2</label>
<title>Methods</title>
<sec id="sec3">
<label>2.1</label>
<title>Human samples</title>
<p>Human post-mortem frozen lumbar spinal cord tissue from SCA3 and control (cause of death not CNS-related) patients was acquired from the University of Maryland, Baltimore, and the University of Florida Center for NeuroGenetics biobanks. See <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S1</xref> for details on sample sex, age, postmortem interval, and ATXN3 CAG repeat size.</p>
</sec>
<sec id="sec4">
<label>2.2</label>
<title>Mouse models</title>
<p>All KI experiments were conducted with heterozygous (<italic>Atxn3</italic><sup>Q300/Q6</sup>) KI mice (<xref ref-type="bibr" rid="ref53">Schuster et al., 2023</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>; <xref ref-type="bibr" rid="ref39">Ramani et al., 2017</xref>; RRID: IMSR_JAX:014603). KI mice in this study were generated by breeding a heterozygous female and wild type (<italic>Atxn3</italic><sup>Q6/Q6</sup>) male mouse to limit further genetic anticipation. <italic>Atxn3</italic> KO (<italic>Atxn3<sup>&#x2212;/&#x2212;</sup></italic>) mice used in these studies were first reported by <xref ref-type="bibr" rid="ref40">Reina et al. (2012)</xref> and further characterized by our lab and others (<xref ref-type="bibr" rid="ref39">Ramani et al., 2017</xref>; <xref ref-type="bibr" rid="ref68">Zeng et al., 2018</xref>; <xref ref-type="bibr" rid="ref54">Schuster et al., 2022a</xref>, <xref ref-type="bibr" rid="ref56">2022b</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>). All mouse lines are maintained on a C57BL/6J background (RRID: IMSR_JAX:000664). See <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S2</xref> for details on the genotype, sex, and age of samples used in sequencing experiments. All animal procedures were approved by the University of Michigan Institutional Animal Care and Use Committee and conducted in accordance with the United States Public Health Service&#x2019;s policy on Humane Care and Use of Laboratory Animals. Mice were housed in a room with standard 12-h light/dark cycles and food and water provided ad libitum.</p>
</sec>
<sec id="sec5">
<label>2.3</label>
<title>Mouse genotyping</title>
<p>Mice were genotyped from tail DNA, biopsied before weaning for study enrollment, and confirmed upon postmortem tissue collection, as previously described (<xref ref-type="bibr" rid="ref53">Schuster et al., 2023</xref>). KI mice were genotyped via PCR amplification of 80&#x202F;ng of DNA using 10x PCR buffer, 5x Q Reagent, 10&#x202F;mM DNTPs, and Taq from the Qiagen Taq PCR core kit per manufacturer&#x2019;s instructions for a 25&#x202F;&#x03BC;L reaction (Qiagen, 201223). Additionally, 4&#x202F;&#x03BC;L of 5 M Betaine (Millipore Sigma, B0300), 1.6&#x202F;&#x03BC;L of 10&#x202F;&#x03BC;M forward and reverse primer, and ddH<sub>2</sub>O up to 25&#x202F;&#x03BC;L were added per reaction. The PCR conditions were 95&#x202F;&#x00B0;C for 2&#x202F;min, followed by 40 cycles of 95&#x202F;&#x00B0;C for 30&#x202F;s, 55.2&#x202F;&#x00B0;C for 1&#x202F;min, and 72&#x202F;&#x00B0;C for 2&#x202F;min and 30&#x202F;s, followed by a final step of 72&#x202F;&#x00B0;C for 10&#x202F;min. Primers flanking the endogenous mouse <italic>Atxn3</italic> CAG repeat (KI forward 5&#x2032;-TTCACGTTTGAATGTTTCAGG-3&#x2032;, KI reverse 5&#x2032;-ATATGAAAGGGGTCCAGGTCG-3&#x2032;) were used for this reaction. KO mice were genotyped via PCR amplification of 50&#x202F;ng of DNA in a 25&#x202F;&#x03BC;L reaction using 2x GoTaq Mix (Promega, M7832), 0.5&#x202F;&#x03BC;L of each primer at 10&#x202F;&#x03BC;M, and ddH<sub>2</sub>O up to 25&#x202F;&#x03BC;L. The PCR conditions were 98&#x202F;&#x00B0;C for 3&#x202F;min, followed by 35&#x202F;cycles of 96&#x202F;&#x00B0;C for 30&#x202F;s, 55&#x202F;&#x00B0;C for 45&#x202F;s, and 72&#x202F;&#x00B0;C for 1&#x202F;min, followed by a final step of 72&#x202F;&#x00B0;C for 5&#x202F;min. Primers used for KO mouse genotyping were: ATXN3KO forward 5&#x2032;-GAGGGAAGTCGTCATAAGAGT-3&#x2032;, ATXN3KO reverse 5&#x2032;-TGGGCTACAAGAAATCCTGTC-3&#x2032;, and ATXN3KO LTRa 5&#x2032;-AAATGGCGTTACTTAAGCTAG-3&#x2032;.</p>
</sec>
<sec id="sec6">
<label>2.4</label>
<title>Tissue collection</title>
<p>Spinal cord tissue was collected at approximately 24&#x202F;weeks of age from KI and KO mice (mean &#x00B1; SEM&#x202F;=&#x202F;24.08&#x202F;&#x00B1;&#x202F;0.12 and 25.03&#x202F;&#x00B1;&#x202F;0.17&#x202F;weeks, respectively) and approximately 56&#x202F;weeks of age from KI mice (56.86&#x202F;&#x00B1;&#x202F;0.29&#x202F;weeks). Mice were anesthetized with a lethal dose of ketamine-xylazine and then transcardially perfused with PBS before the spinal cord was collected via hydraulic expulsion (<xref ref-type="bibr" rid="ref43">Richner et al., 2017</xref>). Cervical spinal cord tissue was flash frozen on dry ice for RNA experiments, and the remaining cord was post-fixed in 4% paraformaldehyde (PFA) for histology experiments.</p>
</sec>
<sec id="sec7">
<label>2.5</label>
<title>RNA extraction and expression analysis</title>
<p>RNA was extracted from PBS-perfused, flash-frozen human and mouse spinal cord tissue, as previously described (<xref ref-type="bibr" rid="ref56">Schuster et al., 2022b</xref>). Tissue was homogenized in RIPA buffer (Sigma Aldrich, R0278) with protease inhibitors (Sigma Aldrich, 11836170001) (1,000&#x202F;&#x03BC;L for human samples and 500&#x202F;&#x03BC;L for mouse samples) using a Next Advance Bullet Blender. Lysate was combined with Trizol (Invitrogen, 15596018), and RNA extraction was performed using QIAshredder (Qiagen, 79654) and RNeasy Plus Mini Kit (Qiagen, 74134), per the manufacturer&#x2019;s protocol. RNA samples were submitted to the University of Michigan Advanced Genomics Core for library preparation and Illumina Next Generation Sequencing on a NovaSeq Flowcell. Mouse libraries were prepared using NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB, E7490) and NEBNext UltraExpress RNA Library Prep Kit (NEB, E3330), while human samples were prepared using NEBNext rRNA Depletion Kit (NEB, E6310) and NEBNext UltraExpress RNA Library Prep Kit (NEB, E3330) due to RIN values less than seven (<xref ref-type="supplementary-material" rid="SM1">Supplementary Tables S1, S2</xref>).</p>
<p>FASTQ files provided by the University of Michigan Advanced Genomics Core underwent quality control using FastQC (version 0.12.1, RRID: SCR_014583) to ensure all samples used had sufficient read depth (&#x003E;75 million paired-end reads) and check the adapter content (<xref ref-type="supplementary-material" rid="SM1">Supplementary Tables S1, S2</xref>). All FASTQ files had &#x003C;20% adapter content, so no trimming was performed. FASTQ files were aligned to the GRCm39 mouse reference genome or GRCh38 human reference genome using STAR (version 2.7.10b, RRID: SCR_004463). Samtools (version 1.21, RRID: SCR_002105) was used to combine the dorsal and ventral spinal cord data from each patient. Differential gene expression was performed in RStudio (2025.05.0+513, RRID: SCR_000432; R version 4.4.2, RRID: SCR_001905) using DESeq2 (version 1.46.0, RRID: SCR_015687). Genes were considered differentially expressed if they passed a significance threshold of Padj &#x003C; 0.05 and log2FC&#x202F;&#x003E;&#x202F;|1.5|. Transcripts per million (TPM) values were calculated using Kallisto (version 0.46.2, RRID: SCR_016582). WGCNA was performed in RStudio using the WGCNA package (version 1.73, RRID: SCR_003302). g: Profiler [(<xref ref-type="bibr" rid="ref22">Kolberg et al., 2023</xref>), RRID: SCR_006809] was used for all gene ontology (GO) analyses. Alternative splicing analysis was performed using rMATS (version 4.1.2, RRID: SCR_023485). Splicing events were considered significant if they passed a significance threshold of FDR&#x202F;&#x003C;&#x202F;0.05 and &#x0394;PSI &#x003E; |0.1|. All &#x0394;PSI values are converted from a ratio to a percentage with a threshold-adjusted &#x0394;PSI &#x003E; |10%| accordingly. Exon numbers are defined by counting from the first exon in the ensemble transcript 201 or by matching coordinates to previous literature.</p>
</sec>
<sec id="sec8">
<label>2.6</label>
<title>Immunohistochemistry</title>
<p>PBS perfused mouse spinal cords were post-fixed for 24&#x202F;h in 4% PFA before being transferred into 30% sucrose in PBS for long-term storage at 4&#x202F;&#x00B0;C. Spinal cords were dissected into 3&#x202F;mm pieces, embedded in spinal racks (<xref ref-type="bibr" rid="ref15">Fiederling et al., 2021</xref>) in OCT (Fisher, 4585) and cryostat-sectioned at 20&#x202F;&#x03BC;m. For NeuN, GFAP, and IBA1 histology experiments, sections underwent a 30-min antigen retrieval in 0.01&#x202F;M sodium citrate buffer (pH 8.5) at 80&#x202F;&#x00B0;C, whereas ASPA histology experiments did not undergo an antigen retrieval step. Immunohistochemistry was performed using the Vectastain ABC-HRP Kit (Vector Laboratories, PK-4000) and DAB Substrate Kit (Vector Laboratories, SK-4100) per manufacturer&#x2019;s protocol. Primary antibodies assessed include: rat anti-NeuN (1:500, Abcam, ab279297, RRID: AB_3095692), rabbit anti-ASPA (1:500, Millipore Sigma, ABN1698, RRID: AB_2827931), mouse anti-GFAP (1:500, Cell Signaling Technology, 3,670&#x202F;s, RRID: AB_561049), and rabbit anti-IBA1 (1:500, Fisher, PIPA521274, RRID: AB_2804971). Coverslips were mounted using DPX mounting media (Electron Microscopy Science, 13510), and imaging was performed using a Nikon Ti2 widefield microscope (RRID: SCR_021068) with a Digital Sight 10 camera.</p>
</sec>
<sec id="sec9">
<label>2.7</label>
<title>Statistics</title>
<p>Statistical analyses were carried out in Microsoft Excel, GraphPad Prism (10.4.1), and RStudio (2025.05.0+513). The PCA plots and WGCNA dendrogram were created in RStudio using ggplot2 and WGCNA. Ellipses on PCA plots represent 95% confidence intervals. Graphs display the mean &#x00B1; SEM with significance levels as follows: ns&#x202F;=&#x202F;not significant, &#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.05, &#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.01, &#x002A;&#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.001, or &#x002A;&#x002A;&#x002A;&#x002A; <italic>p</italic>&#x202F;&#x003C;&#x202F;0.0001.</p>
</sec>
</sec>
<sec sec-type="results" id="sec10">
<label>3</label>
<title>Results</title>
<sec id="sec11">
<label>3.1</label>
<title>Transcriptomic profiling reveals widespread gene dysregulation in human SCA3 spinal cord</title>
<p>Although MRI and post-mortem studies have established pronounced structural changes and atrophy in the spinal cord of SCA3 patients (<xref ref-type="bibr" rid="ref37">Pinto and De Carvalho, 2008</xref>; <xref ref-type="bibr" rid="ref59">Suga et al., 2014</xref>; <xref ref-type="bibr" rid="ref36">Pedroso et al., 2016</xref>). The molecular mechanisms underlying this vulnerability remain poorly defined, and no transcriptional analyses have been reported to date. To address this gap, we performed bulk RNA sequencing on spinal cord samples collected post-mortem from four SCA3 patients and four age-matched controls (non-CNS-related cause of death) (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table S1</xref>). RNA was extracted from frozen spinal cord samples received from the University of Florida and the University of Maryland, Baltimore Brain Banks. Due to suboptimal RNA quality (RIN&#x202F;&#x003C;&#x202F;7), samples were prepared with ribosomal RNA depletion followed by paired-end sequencing, yielding an average of 93.6 million reads per sample (standard deviation 20.4 million) (GSE309548).</p>
<p>Principal component analysis (PCA) demonstrated clear separation between SCA3 and control samples (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Differential gene expression analysis revealed widespread transcriptional dysregulation in the SCA3 spinal cord, with 466 upregulated and 1,189 downregulated differentially expressed genes (DEGs) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S3</xref>). To further interpret these changes, we applied weighted gene co-expression network analysis (WGCNA) to detect groups of co-expressed, functionally related gene modules (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S4</xref>). Of these, two modules&#x2014;brown and yellow&#x2014;were significantly altered in SCA3 samples compared to controls (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Gene ontology (GO) analysis revealed that the brown module was enriched for genes involved in inflammation, while the yellow module was associated with extracellular matrix (ECM) organization (<xref ref-type="fig" rid="fig1">Figures 1D</xref>,<xref ref-type="fig" rid="fig1">E</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S5</xref>). These results align with previous reports of neuroimmune activation and ECM remodeling in SCA3-vulnerable brain regions, including the cerebellum and brainstem (<xref ref-type="bibr" rid="ref10">Evert et al., 2001</xref>; <xref ref-type="bibr" rid="ref45">R&#x00FC;b et al., 2002a</xref>, <xref ref-type="bibr" rid="ref46">2002b</xref>; <xref ref-type="bibr" rid="ref50">Scherzed et al., 2012</xref>; <xref ref-type="bibr" rid="ref26">Liu et al., 2025</xref>). The ECM has previously been implicated in SCA3 disease pathology and may contribute to the structural changes observed in the patient&#x2019;s spinal cord by MRI (<xref ref-type="bibr" rid="ref42">Rezende et al., 2018</xref>, <xref ref-type="bibr" rid="ref41">2024</xref>; <xref ref-type="bibr" rid="ref11">Faber et al., 2021</xref>; <xref ref-type="bibr" rid="ref65">Ye et al., 2025</xref>). Although analysis of human end-stage tissue has highlighted key dysregulated pathways in the SCA3 spinal cord, it does not clarify when these changes arise or how they progress during disease, prompting us to investigate these questions using SCA3 mouse models.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Human post-mortem SCA3 tissue shows significant transcriptional dysregulation. <bold>(A)</bold> PCA plot of gene expression differences from human SCA3 and control (CTRL) spinal cord samples, with ellipses representing 95% confidence intervals for group. <bold>(B)</bold> Volcano plot highlighting significantly upregulated (red) and downregulated (blue) differentially expressed genes between SCA3 and CTRL samples. <bold>(C)</bold> Significant disease-associated weighted gene co-expression network analysis (WGCNA) modules. <bold>(D,E)</bold> Top 10 most significant gene ontology (GO) terms for <bold>(D)</bold> brown and <bold>(E)</bold> yellow WGCNA modules. Frac depicts the fraction of GO term genes included in the dataset.</p>
</caption>
<graphic xlink:href="fncel-19-1735225-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Five-panel composite image depicting data analyses:A) Principal component analysis (PCA) plot with CTRL and SCA3 groups showing variance;B) Volcano plot for human data with Log2 fold change on the x-axis and -Log10(p-adj) on the y-axis, highlighting differentially expressed genes;C) Bar plot of WGCNA module significance with colors grey, red, blue, turquoise, green, yellow, and brown;D) Bubble plot showing yellow module's top GO terms and significance;E) Bubble plot for brown module's top GO terms and significance. Each plot highlights biological terms and statistical significance.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec12">
<label>3.2</label>
<title>Spinal cord transcriptional dysregulation is early and progressive in a SCA3 KI mouse model</title>
<p>To overcome the limitations of end-stage human tissue, we used our KI SCA3 mouse model, which expresses one normal copy of <italic>Atxn3</italic> with ~6 CAG repeats and one disease copy of <italic>Atxn3</italic> with ~300 CAG repeats (<xref ref-type="bibr" rid="ref53">Schuster et al., 2023</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>). These mice develop motor symptoms beginning around 24&#x202F;weeks of age and typically reach end-stage by 56&#x202F;weeks (<xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>). We collected spinal cord RNA at both these timepoints to assess early and progressive transcriptomic changes. RIN values for all samples were greater than or equal to 8.5, allowing for polyA library prep and paired-end sequencing that resulted in an average read count of 96.7 million (standard deviation 7.5 million) at 24&#x202F;weeks and 80.2 million (standard deviation 8.3 million) at 56&#x202F;weeks (GSE309535).</p>
<p>PCA plots demonstrated that 24- and 56-week SCA3 KI mice progressively diverge from age-matched wild type (WT) controls, consistent with early and advancing transcriptomic changes (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Differential gene expression analysis identified 145 DEGs at 24&#x202F;weeks and 413 DEGs at 56&#x202F;weeks (<xref ref-type="fig" rid="fig2">Figures 2B</xref>,<xref ref-type="fig" rid="fig2">C</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S3</xref>). The majority of the 24-week DEGs remain differentially expressed in the same direction at 56&#x202F;weeks (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), supporting progressive transcriptional dysregulation in the SCA3 spinal cord. Unbiased WGCNA revealed six significantly dysregulated gene modules in the KI spinal cord (<xref ref-type="fig" rid="fig2">Figure 2E</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S1</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S4</xref>). Of particular note, the yellow and turquoise modules were consistently significant at both 24- and 56-week timepoints. Yellow module genes function in lipid metabolism pathways (<xref ref-type="fig" rid="fig2">Figure 2F</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S5</xref>), a group of biological functions previously found to be affected by SCA3 in vulnerable brain regions (<xref ref-type="bibr" rid="ref56">Schuster et al., 2022b</xref>, <xref ref-type="bibr" rid="ref53">2023</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>), while the turquoise module represented inflammatory pathways (<xref ref-type="fig" rid="fig2">Figure 2G</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S5</xref>) similar to that seen histologically in SCA3 patient and mouse model pontine tissue (<xref ref-type="bibr" rid="ref10">Evert et al., 2001</xref>; <xref ref-type="bibr" rid="ref29">McLoughlin et al., 2018</xref>). Additionally, the magenta module demonstrated progressive changes and was enriched for terms related to nucleic acid processing and cell development (<xref ref-type="fig" rid="fig2">Figure 2H</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S5</xref>), echoing recent findings that link RNA splicing disturbances to SCA3 pathogenesis (<xref ref-type="bibr" rid="ref57">Shorrock et al., 2023</xref>; <xref ref-type="bibr" rid="ref26">Liu et al., 2025</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Transcriptional dysregulation occurs early and progressively in the spinal cord of SCA3 KIQ300 mice. <bold>(A)</bold> PCA plot of early (24&#x202F;week) and late (56&#x202F;week) stage gene expression differences from KI and WT littermate controls, with ellipses representing 95% confidence intervals. <bold>(B,C)</bold> Volcano plots highlight significantly upregulated (red) and downregulated (blue) differentially expressed genes in <bold>(B)</bold> 24- and <bold>(C)</bold> 56-week samples. <bold>(D)</bold> Venn diagram of overlapping differentially expressed genes in 24- and 56-week spinal cord. <bold>(E)</bold> Significant disease-associated weighted gene co-expression network analysis (WGCNA) modules in 24- and 56-week samples. <bold>(F&#x2013;H)</bold> Top 10 most significant gene ontology (GO) terms for <bold>(F)</bold> yellow, <bold>(G)</bold> turquoise, and <bold>(H)</bold> magenta WGCNA modules. Frac depicts the fraction of GO term genes included in the dataset.</p>
</caption>
<graphic xlink:href="fncel-19-1735225-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">A series of visualizations displaying genetic data analysis. Panel A shows a PCA plot comparing four conditions: 24-week and 56-week wild type (WT) and knock-in (KI) with distinct clusters. Panels B and C present volcano plots for 24-week and 56-week KI groups, highlighting significant gene expression changes with red and blue points. Panel D features Venn diagrams showing overlapping and unique genetic elements between 24-week and 56-week samples. Panel E presents a bar graph of WGCNA modules, indicating significant gene modules with color coding. Panels F, G, and H display bubble plots for GO terms, highlighting significant processes associated with yellow, turquoise, and magenta modules, respectively.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec13">
<label>3.3</label>
<title><italic>Atxn3</italic> knockout spinal cord shows a transcriptional profile distinct from SCA3</title>
<p>To determine the contributions of ATXN3 loss of function to the transcriptomic changes observed in KI mice, we performed RNA sequencing on spinal cords from 24-week <italic>Atxn3</italic> KO mice and their WT littermate controls. All samples had RIN values greater than or equal to 8.9, indicating sufficient quality for polyA library preparation. Sequencing yielded an average of 115 million paired-end reads per sample (standard deviation 12 million) (GSE309549).</p>
<p>PCA showed distinct clustering of the KO mice relative to WT controls (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Differential gene expression analysis revealed substantially fewer DEGs in the KO spinal cord relative to KI mice, with almost all DEGs downregulated (<xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S3</xref>). Comparing the 138 KO DEGs to those in the SCA3 KI datasets showed minimal overlap; only one of twelve shared genes (<italic>Or5v1b</italic>) was dysregulated in the same direction, and notably, <italic>Or5v1b</italic> has no known connection to SCA3 disease (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). To identify major dysregulated cell types, we utilized a published mouse spinal cord atlas (<xref ref-type="bibr" rid="ref47">Russ et al., 2021</xref>) and found no specific cell types overrepresented among KO DEGs (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). In contrast, analysis of the 24-week KI tissue using the same atlas revealed enrichment of microglial genes among DEGs (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), a pattern also observed in the 56-week KI data set (<xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S2</xref>). Importantly, the spinal cord atlas was derived from healthy mice, where astrocytes are quiescent and have gene profiles distinct from activated cells. As a result, transcriptomic analyses using this reference may underestimate reactive astrocyte signatures. Peroxidase-based immunohistochemistry of major CNS cell type markers in 24-week KO spinal cord confirmed the lack of remarkable changes in neurons, oligodendrocytes, astrocytes, or microglia (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). However, in the 24-week KI spinal cord, histological analysis showed decreased expression of a marker for mature oligodendrocytes (ASPA) and increased markers for reactive astrocytes (GFAP) and microglia (IBA1) (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). The affected cell types in the SCA3 spinal cord correspond to those previously reported in vulnerable brain regions and are not dysregulated in the absence of ATXN3 (<xref ref-type="bibr" rid="ref10">Evert et al., 2001</xref>; <xref ref-type="bibr" rid="ref39">Ramani et al., 2017</xref>; <xref ref-type="bibr" rid="ref29">McLoughlin et al., 2018</xref>; <xref ref-type="bibr" rid="ref7">Duarte Lobo et al., 2020</xref>; <xref ref-type="bibr" rid="ref56">Schuster et al., 2022b</xref>, <xref ref-type="bibr" rid="ref53">2023</xref>).</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p><italic>Atxn3</italic> knockout (KO) mouse spinal cords display a distinct transcriptional profile relative to SCA3 KIQ300 mouse spinal cords. <bold>(A)</bold> PCA plot of gene expression data from 24&#x202F;week KO and WT littermate controls, with ellipses representing 95% confidence intervals. <bold>(B)</bold> Volcano plot highlighting upregulated (red) and downregulated (blue) differentially expressed genes (DEGs) in KO samples. Inset bar graph confirms knockdown of <italic>Atxn3</italic> transcripts in KO samples relative to controls. <bold>(C)</bold> Venn diagram shows overlapping DEGs in 24&#x202F;week KO, 24 and 56&#x202F;week KIQ300 spinal cord. <bold>(D)</bold> Heatmap showing cell enrichment and log<sub>2</sub> fold change of <italic>Atxn3</italic> KO DEGs from cell type expression is based on single-nucleus RNA sequencing of mouse spinal cord tissues (<xref ref-type="bibr" rid="ref47">Russ et al., 2021</xref>). <bold>(E)</bold> Heatmap showing cell enrichment and log<sub>2</sub> fold change of spinal cord cell type expression data for 24&#x202F;week KI DEGs (<xref ref-type="bibr" rid="ref47">Russ et al., 2021</xref>). <bold>(F)</bold> Immunohistochemical analysis shows major CNS cell type markers in 24&#x202F;week <italic>Atxn3</italic> KO mouse spinal cord: ASPA representative image from dorsal column. GFAP and IBA1 representative images from the ventral horn. <bold>(G)</bold> Immunohistochemical analysis of major CNS cell type markers in 24&#x202F;week SCA3 KI mouse spinal cord, as in <bold>(E)</bold> (Immunohistochemical studies completed in <italic>n</italic> = 3 mice/genotype, raw images in DANDI archive, DANDI set 001620, NeuN scale bar = 100 &#x03BC;m, all others scale bar = 50 &#x03BC;m).</p>
</caption>
<graphic xlink:href="fncel-19-1735225-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">A composite of scientific figures displays various data related to genetic analysis. A: A principal component analysis (PCA) plot shows variance between wild type (WT) and knockout (KO) samples at 24 weeks.B: A volcano plot with a bar graph inset shows differential gene expression, highlighting significant upregulation of the Atxn3 gene in KO versus WT.C: A Venn diagram compares gene expression changes across different conditions and time points (24 and 56 weeks).D and E: Heatmaps illustrate relative gene expression levels for different gene categories, showing variations in expression across conditions.F and G: Histological images show tissue staining for different proteins (ASPA, GFAP, IBA1, NeuN) in WT, KO, and KI samples, depicting variations in protein expression.</alt-text>
</graphic>
</fig>
</sec>
<sec id="sec14">
<label>3.4</label>
<title>RNA splicing is dysregulated in the SCA3 spinal cord</title>
<p>Recent studies have uncovered significant RNA splicing dysregulation in SCA3, particularly affecting genes involved in synaptic signaling and the cytoskeleton (<xref ref-type="bibr" rid="ref57">Shorrock et al., 2023</xref>; <xref ref-type="bibr" rid="ref1">Aliyeva et al., 2025</xref>; <xref ref-type="bibr" rid="ref23">Lauerer et al., 2025</xref>; <xref ref-type="bibr" rid="ref26">Liu et al., 2025</xref>). To determine if similar splicing alterations occur in our spinal cord datasets, we systematically analyzed five types of alternative splicing events, alternative 3&#x2032; start site (A3SS), alternative 5&#x2032; start site (A5SS), mutually exclusive exons (MXE), retained intron (RI), and skipped exon (SE), setting significance cutoffs of FDR&#x202F;&#x003C;&#x202F;0.05 and |PSI|&#x202F;&#x003E;&#x202F;0.1. The 56-week SCA3 KI spinal cord samples exhibited more significant alternative splicing events than the 24-week KI and KO samples, with SE events comprising the majority in all data sets (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). KO mice showed slightly more significant splicing events than the 24-week KI mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>), but there was very little overlap between significant splicing events between models (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Given that SE events dominated the splicing changes and mirrored findings from prior SCA3 studies, we further characterized these events. In all datasets, SE events showed roughly equal distribution between exon inclusion and exclusion when compared to WT controls (<xref ref-type="fig" rid="fig4">Figure 4C</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S6</xref>). GO analysis of SE events in mouse and human datasets consistently highlighted enrichment of terms related to cytoskeletal structure and cell projections (<xref ref-type="fig" rid="fig4">Figures 4D</xref>&#x2013;<xref ref-type="fig" rid="fig4">F</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure S3</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary Table S7</xref>). This overlap in SE-derived GO terms between KI and KO datasets was surprising to us, especially considering the minimal number of shared events in these datasets. We hypothesize this is because GO uses genes as inputs rather than skipped exon events, and of the unique events in the KI and KO datasets, there is a large portion of commonly affected genes. So, while these genes are affected differently at the splicing level in KI and KO tissue, they are contributing to the GO analysis in the same way. This is a limitation of using GO with alternative splicing data, and so we moved to look at the SE events shared between our KI datasets. In plotting the events that were dysregulated in the same direction in the 24- and 56-week KI datasets (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), we made two key observations. First, many KI SE events, such as <italic>Bcas1</italic>, <italic>Itpr1</italic>, and <italic>Kcnma1</italic>, were previously found to be early and progressively dysregulated in the cerebellum of two other mouse models of SCA3 and a mouse model of SCA1 (<xref ref-type="bibr" rid="ref57">Shorrock et al., 2023</xref>). Additionally, several events shared across our KI datasets are related to oligodendrocytes (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). The first gene, <italic>Enpp2</italic>, is a marker of mature, myelinating oligodendrocytes and has been implicated in several neurodegenerative disorders (<xref ref-type="bibr" rid="ref2">Aston et al., 2005</xref>; <xref ref-type="bibr" rid="ref66">Yuelling et al., 2012</xref>). <italic>Bcas1</italic>, previously found to be dysregulated in the cerebellum of SCA3 mice, is associated with specific populations of myelinating oligodendrocytes in the context of Multiple Sclerosis (<xref ref-type="bibr" rid="ref13">Fard et al., 2017</xref>; <xref ref-type="bibr" rid="ref17">Ishimoto et al., 2017</xref>; <xref ref-type="bibr" rid="ref57">Shorrock et al., 2023</xref>). <italic>Mag</italic> encodes a key structural myelin component, and splicing changes or mutations in Mag have been linked to myelination deficits and ataxic symptoms (<xref ref-type="bibr" rid="ref64">Wu et al., 2002</xref>; <xref ref-type="bibr" rid="ref44">Roda et al., 2016</xref>; <xref ref-type="bibr" rid="ref48">Santos et al., 2020</xref>; <xref ref-type="bibr" rid="ref67">Zech et al., 2020</xref>). <italic>Bin1</italic> splicing has also been associated with changes in oligodendrocyte function in Alzheimer&#x2019;s Disease (<xref ref-type="bibr" rid="ref5">De Rossi et al., 2016</xref>). Overall, the persistence of splicing changes in these genes connected to common pathological mechanisms in SCA3 suggests that splicing may be an important driver of disease and warrants further investigation.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>RNA splicing is dysregulated in the spinal cord of SCA3 mouse models. <bold>(A)</bold> Percentage of significantly mis-spliced skipped exon (SE), retained intron (RI), mutually exclusive exons (MXE), alternative 5&#x2032; splice site (A5SS), and alternative 3&#x2032; splice site (A3SS) events as a proportion of all significant splicing events in 24-week KO, 24-week KI, and 56-week KI spinal cord datasets, FDR&#x202F;&#x003C;&#x202F;0.05, &#x0394;PSI &#x003E; 10%. <bold>(B)</bold> Venn diagram of SE events that overlap, at all six coordinates, between datasets. <bold>(C)</bold> Percentage of exon inclusion (positive) or exclusion (negative) for significant SE events in each dataset, FDR&#x202F;&#x003C;&#x202F;0.05, &#x0394;PSI &#x003E; 10%. <bold>(D)</bold> Top 10 gene ontology (GO) terms derived from <italic>Atxn3</italic> KO mouse SE events. <bold>(E)</bold> Top 10 GO terms derived from 24-week KI SE events. <bold>(F)</bold> GO terms derived from 56-week KI SE events. <bold>(G)</bold> Heatmap showing average percent spliced-in (PSI) of SE events shared between 24- and 56-week KI datasets, but not in the 24-week KO dataset. Frac depicts the fraction of GO term genes included in the dataset. <bold>(H)</bold> Violin plots of select oligodendrocyte-related genes with significant SE dysregulated in KI mice. Parentheses denote (upstream exon-skipped exon-downstream exon).</p>
</caption>
<graphic xlink:href="fncel-19-1735225-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Diagram with multiple panels analyzing splicing events in gene expression studies. Panel A shows a bar graph of significant splicing events by type and age group. Panel B presents a Venn diagram of gene inclusion or exclusion events. Panel C features a plot of percentage inclusion or exclusion across groups. Panels D, E, and F display dot plots of gene ontology (GO) terms against statistical significance. Panel G includes a heatmap of percent spliced in (PSI) values for different genes. Panel H consists of violin plots for PSI values in specific exons across various time points and conditions.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="sec15">
<label>4</label>
<title>Discussion</title>
<p>Despite decades of research focused on cerebellar degeneration in SCA3, the spinal cord has now emerged as another key driver of early disease processes and symptom progression, yet its underlying molecular pathology remains largely unexplored (<xref ref-type="bibr" rid="ref42">Rezende et al., 2018</xref>, <xref ref-type="bibr" rid="ref41">2024</xref>; <xref ref-type="bibr" rid="ref11">Faber et al., 2021</xref>; <xref ref-type="bibr" rid="ref65">Ye et al., 2025</xref>). Our study offers the first in-depth transcriptional interrogation of this vulnerable region, revealing a complex interplay of early and progressive gene expression and splicing disruptions that extend beyond the brainstem and cerebellar regions typically associated with SCA3. We established toxic gain-of-function transcriptional signatures and pathology in the SCA3 spinal cord consistent with previous reports in other brain regions, providing groundwork for future mechanistic and therapeutic studies (<xref ref-type="bibr" rid="ref52">Schmitt et al., 2007</xref>; <xref ref-type="bibr" rid="ref40">Reina et al., 2012</xref>; <xref ref-type="bibr" rid="ref39">Ramani et al., 2017</xref>; <xref ref-type="bibr" rid="ref54">Schuster et al., 2022a</xref>, <xref ref-type="bibr" rid="ref56">2022b</xref>, <xref ref-type="bibr" rid="ref55">2024</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>).</p>
<p>A notable finding from both human SCA3 and KI mouse data is that transcriptional dysregulation in the spinal cord involves great changes to lipid metabolism, inflammation, and extracellular matrix composition. These processes are increasingly recognized as central players in neurodegeneration. Importantly, they mirror pathological mechanisms previously established in other SCA3-affected brain regions, including changes in oligodendrocyte maturation (<xref ref-type="bibr" rid="ref56">Schuster et al., 2022b</xref>, <xref ref-type="bibr" rid="ref53">2023</xref>), inflammation (<xref ref-type="bibr" rid="ref10">Evert et al., 2001</xref>; <xref ref-type="bibr" rid="ref45">R&#x00FC;b et al., 2002a</xref>, <xref ref-type="bibr" rid="ref46">2002b</xref>; <xref ref-type="bibr" rid="ref50">Scherzed et al., 2012</xref>), cytoskeletal function (<xref ref-type="bibr" rid="ref32">Neves-Carvalho et al., 2015</xref>; <xref ref-type="bibr" rid="ref63">Wiatr et al., 2019</xref>, <xref ref-type="bibr" rid="ref62">2021</xref>), and nucleic acid biology (<xref ref-type="bibr" rid="ref20">Kazachkova et al., 2013</xref>; <xref ref-type="bibr" rid="ref3">Chatterjee et al., 2015</xref>). Previous work from our group showed that altered lipid metabolism and impaired oligodendrocyte maturation begin prior to symptom onset in the brain, and now, as supported by the current data, in the spinal cord as well (<xref ref-type="bibr" rid="ref56">Schuster et al., 2022b</xref>, <xref ref-type="bibr" rid="ref53">2023</xref>; <xref ref-type="bibr" rid="ref38">Putka et al., 2025</xref>). Evidence of downregulation of mature oligodendrocyte markers, along with disrupted lipid metabolism genes, supports a spinal cord component to white matter pathology in SCA3. These molecular changes may underlie the early and robust atrophy seen in imaging studies of the patient&#x2019;s spinal cord (<xref ref-type="bibr" rid="ref42">Rezende et al., 2018</xref>, <xref ref-type="bibr" rid="ref41">2024</xref>; <xref ref-type="bibr" rid="ref11">Faber et al., 2021</xref>; <xref ref-type="bibr" rid="ref65">Ye et al., 2025</xref>) and provide concrete mechanistic links between cellular dysfunction and structural neurodegeneration.</p>
<p>Previous studies in SCA3 vulnerable brain regions, including the brainstem and pons, have documented astrocytic and microglial reactivity similar to our spinal cord findings (<xref ref-type="bibr" rid="ref10">Evert et al., 2001</xref>; <xref ref-type="bibr" rid="ref45">R&#x00FC;b et al., 2002a</xref>, <xref ref-type="bibr" rid="ref46">2002b</xref>; <xref ref-type="bibr" rid="ref50">Scherzed et al., 2012</xref>). However, the inflammatory spinal cord signatures were prevalent even at early symptomatic stages in this KI mouse model. This challenges the prevailing view that neuroinflammation is merely a late or reactive pathology, suggesting instead that it may have a more active role in SCA3 dysfunction within the spinal cord. Whether this inflammation is a cause or consequence of glial and neuronal dysregulation remains unclear; however, our data highlight it as an important target for future mechanistic and therapeutic studies.</p>
<p>Our transcriptomic analyses also uncovered significant splicing alterations, especially in genes governing cytoskeletal structure and myelination. These results align with recent studies implicating aberrant RNA processing as a cross-disease mechanism in polyglutamine disorders and expand it to the spinal cord in SCA3 mouse and human tissue (<xref ref-type="bibr" rid="ref4">Daughters et al., 2009</xref>; <xref ref-type="bibr" rid="ref31">Mykowska et al., 2011</xref>; <xref ref-type="bibr" rid="ref24">Li et al., 2016</xref>; <xref ref-type="bibr" rid="ref25">Lin et al., 2016</xref>; <xref ref-type="bibr" rid="ref51">Schilling et al., 2019</xref>; <xref ref-type="bibr" rid="ref9">Elorza et al., 2021</xref>; <xref ref-type="bibr" rid="ref33">Olmos et al., 2023</xref>; <xref ref-type="bibr" rid="ref57">Shorrock et al., 2023</xref>; <xref ref-type="bibr" rid="ref1">Aliyeva et al., 2025</xref>). The observed dysregulation of <italic>Bcas1</italic>, <italic>Mag</italic>, <italic>Bin1</italic>, and <italic>Enpp2</italic> splicing, genes central to myelination by oligodendrocytes (<xref ref-type="bibr" rid="ref64">Wu et al., 2002</xref>; <xref ref-type="bibr" rid="ref66">Yuelling et al., 2012</xref>; <xref ref-type="bibr" rid="ref5">De Rossi et al., 2016</xref>; <xref ref-type="bibr" rid="ref13">Fard et al., 2017</xref>; <xref ref-type="bibr" rid="ref17">Ishimoto et al., 2017</xref>), provides a tantalizing molecular link between RNA splicing defects and impaired myelin maintenance in SCA3 (<xref ref-type="bibr" rid="ref56">Schuster et al., 2022b</xref>, <xref ref-type="bibr" rid="ref53">2023</xref>). It remains to be seen whether these splicing changes precede, drive, or result from other pathological alterations in the diseased spinal cord.</p>
<p>Our findings suggest that the spinal cord is not simply a downstream casualty of SCA3 brain pathology, but rather another primary site of early and progressive molecular dysfunction. The fact that spinal cord atrophy emerges before overt ataxia in patients by MRI and closely tracks with disease severity, highlights its strong potential as a biomarker for monitoring disease progression and evaluating therapeutic responses. At the same time, the early and multifaceted nature of molecular disruption in the spinal cord, encompassing transcriptomic, splicing, metabolic, and inflammatory changes, raises pivotal questions about which cell types are most critical in disease onset, whether these molecular alterations represent parallel or interconnected pathogenic pathways, and importantly, whether such changes can be targeted or reversed to alter SCA3 progression. In summary, our study is the first to position the spinal cord as a central player in SCA3 pathogenesis with both commonalities and distinctions from other vulnerable regions, and by identifying fundamental molecular changes at early disease stages, provides an essential framework for future research to decipher pathogenic mechanisms and ultimately guide the development of targeted, effective therapies for this devastating disorder.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec16">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>.</p>
</sec>
<sec sec-type="ethics-statement" id="sec17">
<title>Ethics statement</title>
<p>The studies involving humans were approved by the University of Maryland Institutional Review Board (IRB: HM-HP-00042077), the Maryland Department of Health and Mental Hygiene Institutional Review Board (IRB: 5-58), the University of Florida Institutional Review Board (IRB: 201500232). The participants provided their written informed consent to participate in this study. The animal study was approved by University of Michigan Institutional Animal Care and Use committee. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="sec18">
<title>Author contributions</title>
<p>JE: Investigation, Writing &#x2013; original draft, Formal analysis, Visualization, Funding acquisition, Data curation, Validation, Conceptualization, Methodology, Writing &#x2013; review &#x0026; editing. BN: Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft, Investigation, Data curation, Formal analysis, Visualization. EW: Formal analysis, Visualization, Data curation, Writing &#x2013; review &#x0026; editing, Writing &#x2013; original draft, Investigation. GM: Data curation, Visualization, Formal analysis, Writing &#x2013; review &#x0026; editing, Investigation, Writing &#x2013; original draft. HS: Validation, Formal analysis, Data curation, Visualization, Methodology, Writing &#x2013; review &#x0026; editing, Funding acquisition, Supervision, Investigation, Writing &#x2013; original draft. HM: Conceptualization, Funding acquisition, Validation, Supervision, Writing &#x2013; review &#x0026; editing, Methodology, Formal analysis, Visualization, Writing &#x2013; original draft, Resources.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>Figure schematics created using <ext-link xlink:href="http://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>. The authors thank Dr. Maria do Carmo Costa for the gift of the KIQ300 mouse model used in these studies and Dr. David Burke for printing spinal racks used to section spinal cord tissue. The authors thank the University of Florida and University of Baltimore Maryland (NIH Neurobiobank) Brain Banks for providing the human spinal cord tissue used in this study.</p>
</ack>
<sec sec-type="COI-statement" id="sec19">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec20">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec21">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec22">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fncel.2025.1735225/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fncel.2025.1735225/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Data_Sheet_1.PDF" id="SM8" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_1.XLSX" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.XLSX" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_3.XLSX" id="SM3" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_4.XLSX" id="SM4" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_5.XLSX" id="SM5" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_6.XLSX" id="SM6" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_7.XLSX" id="SM7" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliyeva</surname><given-names>A.</given-names></name> <name><surname>Lennon</surname><given-names>C. D.</given-names></name> <name><surname>Cleary</surname><given-names>J. D.</given-names></name> <name><surname>Shorrock</surname><given-names>H. K.</given-names></name> <name><surname>Berglund</surname><given-names>J. A.</given-names></name></person-group> (<year>2025</year>). <article-title>Dysregulation of alternative splicing is a transcriptomic feature of patient-derived fibroblasts from CAG repeat expansion spinocerebellar ataxias</article-title>. <source>Hum. Mol. Genet.</source> <volume>34</volume>, <fpage>239</fpage>&#x2013;<lpage>250</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddae174</pub-id>, <pub-id pub-id-type="pmid">39589088</pub-id></mixed-citation></ref>
<ref id="ref2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aston</surname><given-names>C.</given-names></name> <name><surname>Jiang</surname><given-names>L.</given-names></name> <name><surname>Sokolov</surname><given-names>B. P.</given-names></name></person-group> (<year>2005</year>). <article-title>Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder</article-title>. <source>Mol. Psychiatry</source> <volume>10</volume>, <fpage>309</fpage>&#x2013;<lpage>322</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.mp.4001565</pub-id>, <pub-id pub-id-type="pmid">15303102</pub-id></mixed-citation></ref>
<ref id="ref3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>A.</given-names></name> <name><surname>Saha</surname><given-names>S.</given-names></name> <name><surname>Chakraborty</surname><given-names>A.</given-names></name> <name><surname>Silva-Fernandes</surname><given-names>A.</given-names></name> <name><surname>Mandal</surname><given-names>S. M.</given-names></name> <name><surname>Neves-Carvalho</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3&#x2019;-phosphatase in spinocerebellar Ataxia type 3 pathogenesis</article-title>. <source>PLoS Genet.</source> <volume>11</volume>:<fpage>e1004749</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1004749</pub-id>, <pub-id pub-id-type="pmid">25633985</pub-id></mixed-citation></ref>
<ref id="ref4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daughters</surname><given-names>R. S.</given-names></name> <name><surname>Tuttle</surname><given-names>D. L.</given-names></name> <name><surname>Gao</surname><given-names>W.</given-names></name> <name><surname>Ikeda</surname><given-names>Y.</given-names></name> <name><surname>Moseley</surname><given-names>M. L.</given-names></name> <name><surname>Ebner</surname><given-names>T. J.</given-names></name> <etal/></person-group>. (<year>2009</year>). <article-title>RNA gain-of-function in spinocerebellar Ataxia type 8</article-title>. <source>PLoS Genet.</source> <volume>5</volume>:<fpage>e1000600</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1000600</pub-id>, <pub-id pub-id-type="pmid">19680539</pub-id></mixed-citation></ref>
<ref id="ref5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rossi</surname><given-names>P.</given-names></name> <name><surname>Buggia-Pr&#x00E9;vot</surname><given-names>V.</given-names></name> <name><surname>Clayton</surname><given-names>B. L. L.</given-names></name> <name><surname>Vasquez</surname><given-names>J. B.</given-names></name> <name><surname>van Sanford</surname><given-names>C.</given-names></name> <name><surname>Andrew</surname><given-names>R. J.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Predominant expression of Alzheimer&#x2019;s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts</article-title>. <source>Mol. Neurodegener.</source> <volume>11</volume>:<fpage>59</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13024-016-0124-1</pub-id></mixed-citation></ref>
<ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diallo</surname><given-names>A.</given-names></name> <name><surname>Jacobi</surname><given-names>H.</given-names></name> <name><surname>Cook</surname><given-names>A.</given-names></name> <name><surname>Labrum</surname><given-names>R.</given-names></name> <name><surname>Durr</surname><given-names>A.</given-names></name> <name><surname>Brice</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study</article-title>. <source>The Lancet Neurology</source> <volume>17</volume>, <fpage>327</fpage>&#x2013;<lpage>334</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(18)30042-5</pub-id>, <pub-id pub-id-type="pmid">29553382</pub-id></mixed-citation></ref>
<ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duarte Lobo</surname><given-names>D.</given-names></name> <name><surname>Nobre</surname><given-names>R. J.</given-names></name> <name><surname>Oliveira Miranda</surname><given-names>C.</given-names></name> <name><surname>Pereira</surname><given-names>D.</given-names></name> <name><surname>Castelhano</surname><given-names>J.</given-names></name> <name><surname>Sereno</surname><given-names>J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>The blood-brain barrier is disrupted in Machado-Joseph disease/spinocerebellar ataxia type 3: evidence from transgenic mice and human post-mortem samples</article-title>. <source>Acta Neuropathol. Commun.</source> <volume>8</volume>:<fpage>152</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40478-020-00955-0</pub-id>, <pub-id pub-id-type="pmid">32867861</pub-id></mixed-citation></ref>
<ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durr</surname><given-names>A.</given-names></name> <name><surname>Stevanin</surname><given-names>G.</given-names></name> <name><surname>Cancel</surname><given-names>G.</given-names></name> <name><surname>Duyckaerts</surname><given-names>C.</given-names></name> <name><surname>Abbas</surname><given-names>N.</given-names></name> <name><surname>Didierjean</surname><given-names>O.</given-names></name> <etal/></person-group>. (<year>1996</year>). <article-title>Spinocerebellar ataxia 3 and Machado-joseph disease: clinical, molecular, and neuropathological features</article-title>. <source>Ann. Neurol.</source> <volume>39</volume>, <fpage>490</fpage>&#x2013;<lpage>499</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.410390411</pub-id>, <pub-id pub-id-type="pmid">8619527</pub-id></mixed-citation></ref>
<ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elorza</surname><given-names>A.</given-names></name> <name><surname>M&#x00E1;rquez</surname><given-names>Y.</given-names></name> <name><surname>Cabrera</surname><given-names>J. R.</given-names></name> <name><surname>S&#x00E1;nchez-Trincado</surname><given-names>J. L.</given-names></name> <name><surname>Santos-Galindo</surname><given-names>M.</given-names></name> <name><surname>Hern&#x00E1;ndez</surname><given-names>I. H.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Huntington&#x2019;s disease-specific mis-splicing unveils key effector genes and altered splicing factors</article-title>. <source>Brain</source> <volume>144</volume>, <fpage>2009</fpage>&#x2013;<lpage>2023</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awab087</pub-id>, <pub-id pub-id-type="pmid">33725094</pub-id></mixed-citation></ref>
<ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evert</surname><given-names>B. O.</given-names></name> <name><surname>Vogt</surname><given-names>I. R.</given-names></name> <name><surname>Kindermann</surname><given-names>C.</given-names></name> <name><surname>Ozimek</surname><given-names>L.</given-names></name> <name><surname>de Vos</surname><given-names>R. A. I.</given-names></name> <name><surname>Brunt</surname><given-names>E. R. P.</given-names></name> <etal/></person-group>. (<year>2001</year>). <article-title>Inflammatory genes are upregulated in expanded Ataxin-3-expressing cell lines and spinocerebellar Ataxia type 3 brains</article-title>. <source>J. Neurosci.</source> <volume>21</volume>, <fpage>5389</fpage>&#x2013;<lpage>5396</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.21-15-05389.2001</pub-id>, <pub-id pub-id-type="pmid">11466410</pub-id></mixed-citation></ref>
<ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faber</surname><given-names>J.</given-names></name> <name><surname>Schaprian</surname><given-names>T.</given-names></name> <name><surname>Berkan</surname><given-names>K.</given-names></name> <name><surname>Reetz</surname><given-names>K.</given-names></name> <name><surname>Fran&#x00E7;a</surname><given-names>M. C.</given-names> <suffix>Jr.</suffix></name> <name><surname>de Rezen</surname><given-names>T. J. R.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Regional brain and spinal cord volume loss in spinocerebellar Ataxia type 3</article-title>. <source>Mov. Disord.</source> <volume>36</volume>, <fpage>2273</fpage>&#x2013;<lpage>2281</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.28610</pub-id></mixed-citation></ref>
<ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahl</surname><given-names>C. N.</given-names></name> <name><surname>Branco</surname><given-names>L. M. T.</given-names></name> <name><surname>Bergo</surname><given-names>F. P. G.</given-names></name> <name><surname>D&#x2019;Abreu</surname><given-names>A.</given-names></name> <name><surname>Lopes-Cendes</surname><given-names>I.</given-names></name> <name><surname>Fran&#x00E7;a</surname><given-names>M. C.</given-names></name></person-group> (<year>2015</year>). <article-title>Spinal cord damage in Machado-Joseph disease</article-title>. <source>Cerebellum</source> <volume>14</volume>, <fpage>128</fpage>&#x2013;<lpage>132</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-014-0619-7</pub-id></mixed-citation></ref>
<ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fard</surname><given-names>M. K.</given-names></name> <name><surname>van der Meer</surname><given-names>F.</given-names></name> <name><surname>S&#x00E1;nchez</surname><given-names>P.</given-names></name> <name><surname>Cantuti-Castelvetri</surname><given-names>L.</given-names></name> <name><surname>Mandad</surname><given-names>S.</given-names></name> <name><surname>J&#x00E4;kel</surname><given-names>S.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions</article-title>. <source>Sci. Transl. Med.</source> <volume>9</volume>:<fpage>eaam7816</fpage>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.aam7816</pub-id>, <pub-id pub-id-type="pmid">29212715</pub-id></mixed-citation></ref>
<ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>M.</given-names></name> <name><surname>Schaprian</surname><given-names>T.</given-names></name> <name><surname>K&#x00FC;gler</surname><given-names>D.</given-names></name> <name><surname>Reuter</surname><given-names>M.</given-names></name> <name><surname>Deike-Hoffmann</surname><given-names>K.</given-names></name> <name><surname>Timmann</surname><given-names>D.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Cerebellar volumetry in ataxias: relation to Ataxia severity and duration</article-title>. <source>Cerebellum</source> <volume>23</volume>: <fpage>1521</fpage>&#x2013;<lpage>1529</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-024-01659-0</pub-id>, <pub-id pub-id-type="pmid">38363498</pub-id></mixed-citation></ref>
<ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiederling</surname><given-names>F.</given-names></name> <name><surname>Hammond</surname><given-names>L. A.</given-names></name> <name><surname>Ng</surname><given-names>D.</given-names></name> <name><surname>Mason</surname><given-names>C.</given-names></name> <name><surname>Dodd</surname><given-names>J.</given-names></name></person-group> (<year>2021</year>). <article-title>Tools for efficient analysis of neurons in a 3D reference atlas of whole mouse spinal cord</article-title>. <source>Cell Rep. Methods</source> <volume>1</volume>:<fpage>100074</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.crmeth.2021.100074</pub-id>, <pub-id pub-id-type="pmid">34661190</pub-id></mixed-citation></ref>
<ref id="ref16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimar&#x00E3;es</surname><given-names>R. P.</given-names></name> <name><surname>D&#x2019;Abreu</surname><given-names>A.</given-names></name> <name><surname>Yasuda</surname><given-names>C. L.</given-names></name> <name><surname>Fran&#x00E7;a</surname><given-names>M. C.</given-names></name> <name><surname>Silva</surname><given-names>B. H. B.</given-names></name> <name><surname>Cappabianco</surname><given-names>F. A. M.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3</article-title>. <source>Mov. Disord.</source> <volume>28</volume>, <fpage>1125</fpage>&#x2013;<lpage>1132</lpage>. doi: <pub-id pub-id-type="doi">10.1002/mds.25451</pub-id></mixed-citation></ref>
<ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimoto</surname><given-names>T.</given-names></name> <name><surname>Ninomiya</surname><given-names>K.</given-names></name> <name><surname>Inoue</surname><given-names>R.</given-names></name> <name><surname>Koike</surname><given-names>M.</given-names></name> <name><surname>Uchiyama</surname><given-names>Y.</given-names></name> <name><surname>Mori</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>Mice lacking BCAS1, a novel myelin-associated protein, display hypomyelination, schizophrenia-like abnormal behaviors, and upregulation of inflammatory genes in the brain</article-title>. <source>Glia</source> <volume>65</volume>, <fpage>727</fpage>&#x2013;<lpage>739</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.23129</pub-id></mixed-citation></ref>
<ref id="ref18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>J. S.</given-names></name> <name><surname>Klein</surname><given-names>J. C.</given-names></name> <name><surname>Baudrexel</surname><given-names>S.</given-names></name> <name><surname>Deichmann</surname><given-names>R.</given-names></name> <name><surname>Nolte</surname><given-names>D.</given-names></name> <name><surname>Hilker</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>White matter damage is related to ataxia severity in SCA3</article-title>. <source>J. Neurol.</source> <volume>261</volume>, <fpage>291</fpage>&#x2013;<lpage>299</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-013-7186-6</pub-id></mixed-citation></ref>
<ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaguchi</surname><given-names>Y.</given-names></name> <name><surname>Okamoto</surname><given-names>T.</given-names></name> <name><surname>Taniwaki</surname><given-names>M.</given-names></name> <name><surname>Aizawa</surname><given-names>M.</given-names></name> <name><surname>Inoue</surname><given-names>M.</given-names></name> <name><surname>Katayama</surname><given-names>S.</given-names></name> <etal/></person-group>. (<year>1994</year>). <article-title>CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1</article-title>. <source>Nat. Genet.</source> <volume>8</volume>, <fpage>221</fpage>&#x2013;<lpage>228</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ng1194-221</pub-id>, <pub-id pub-id-type="pmid">7874163</pub-id></mixed-citation></ref>
<ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazachkova</surname><given-names>N.</given-names></name> <name><surname>Raposo</surname><given-names>M.</given-names></name> <name><surname>Montiel</surname><given-names>R.</given-names></name> <name><surname>Cymbron</surname><given-names>T.</given-names></name> <name><surname>Bettencourt</surname><given-names>C.</given-names></name> <name><surname>Silva-Fernandes</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Patterns of mitochondrial DNA damage in blood and brain tissues of a transgenic mouse model of Machado-Joseph disease</article-title>. <source>Neurodegener. Dis.</source> <volume>11</volume>, <fpage>206</fpage>&#x2013;<lpage>214</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000339207</pub-id></mixed-citation></ref>
<ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeppen</surname><given-names>A. H.</given-names></name></person-group> (<year>2018</year>). <article-title>The neuropathology of spinocerebellar Ataxia type 3/Machado-Joseph disease</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1049</volume>, <fpage>233</fpage>&#x2013;<lpage>241</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-3-319-71779-1_11</pub-id>, <pub-id pub-id-type="pmid">29427106</pub-id></mixed-citation></ref>
<ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolberg</surname><given-names>L.</given-names></name> <name><surname>Raudvere</surname><given-names>U.</given-names></name> <name><surname>Kuzmin</surname><given-names>I.</given-names></name> <name><surname>Adler</surname><given-names>P.</given-names></name> <name><surname>Vilo</surname><given-names>J.</given-names></name> <name><surname>Peterson</surname><given-names>H.</given-names></name></person-group> (<year>2023</year>). <article-title>G:profiler&#x2014;interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update)</article-title>. <source>Nucleic Acids Res.</source> <volume>51</volume>, <fpage>W207</fpage>&#x2013;<lpage>W212</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkad347</pub-id>, <pub-id pub-id-type="pmid">37144459</pub-id></mixed-citation></ref>
<ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauerer</surname><given-names>M.</given-names></name> <name><surname>Faber</surname><given-names>J.</given-names></name> <name><surname>Casadei</surname><given-names>N.</given-names></name> <name><surname>Santana</surname><given-names>M. M.</given-names></name> <name><surname>Auburger</surname><given-names>G.</given-names></name> <name><surname>Pogoda</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Influence of ATXN2 intermediate CAG repeats, 9bp duplication and alternative splicing on SCA3 pathogenesis</article-title>. <source>Acta Neuropathol. Commun.</source> <volume>13</volume>:<fpage>157</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40478-025-02074-0</pub-id>, <pub-id pub-id-type="pmid">40684213</pub-id></mixed-citation></ref>
<ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P. P.</given-names></name> <name><surname>Sun</surname><given-names>X.</given-names></name> <name><surname>Xia</surname><given-names>G.</given-names></name> <name><surname>Arbez</surname><given-names>N.</given-names></name> <name><surname>Paul</surname><given-names>S.</given-names></name> <name><surname>Zhu</surname><given-names>S.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis</article-title>. <source>Ann. Neurol.</source> <volume>80</volume>, <fpage>600</fpage>&#x2013;<lpage>615</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.24761</pub-id>, <pub-id pub-id-type="pmid">27531668</pub-id></mixed-citation></ref>
<ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.</given-names></name> <name><surname>Park</surname><given-names>J. W.</given-names></name> <name><surname>Ramachandran</surname><given-names>S.</given-names></name> <name><surname>Zhang</surname><given-names>Y.</given-names></name> <name><surname>Tseng</surname><given-names>Y.-T.</given-names></name> <name><surname>Shen</surname><given-names>S.</given-names></name> <etal/></person-group>. (<year>2016</year>). <article-title>Transcriptome sequencing reveals aberrant alternative splicing in Huntington&#x2019;s disease</article-title>. <source>Hum. Mol. Genet.</source> <volume>25</volume>, <fpage>3454</fpage>&#x2013;<lpage>3466</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddw187</pub-id>, <pub-id pub-id-type="pmid">27378699</pub-id></mixed-citation></ref>
<ref id="ref26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name> <name><surname>Wang</surname><given-names>X.</given-names></name> <name><surname>Xu</surname><given-names>C.</given-names></name> <name><surname>Liu</surname><given-names>X.</given-names></name> <name><surname>Ke</surname><given-names>L.</given-names></name> <name><surname>Li</surname><given-names>Y.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Long-read sequencing identifies ATXN3 repeat expansions, and transcriptomics reveals disease progression biomarkers and druggable targets for spinocerebellar ataxia type 3</article-title>. <source>BMC Neurol.</source> <volume>25</volume>:<fpage>370</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12883-025-04378-z</pub-id>, <pub-id pub-id-type="pmid">40890629</pub-id></mixed-citation></ref>
<ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukas</surname><given-names>C.</given-names></name> <name><surname>Hahn</surname><given-names>H. K.</given-names></name> <name><surname>Bellenberg</surname><given-names>B.</given-names></name> <name><surname>Hellwig</surname><given-names>K.</given-names></name> <name><surname>Globas</surname><given-names>C.</given-names></name> <name><surname>Schimrigk</surname><given-names>S. K.</given-names></name> <etal/></person-group>. (<year>2008</year>). <article-title>Spinal cord atrophy in spinocerebellar ataxia type 3 and 6</article-title>. <source>J. Neurol.</source> <volume>255</volume>, <fpage>1244</fpage>&#x2013;<lpage>1249</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00415-008-0907-6</pub-id>, <pub-id pub-id-type="pmid">18506570</pub-id></mixed-citation></ref>
<ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>C. A.</given-names></name> <name><surname>de Almeida</surname><given-names>L. P.</given-names></name> <name><surname>N&#x00F3;brega</surname><given-names>C.</given-names></name></person-group> (<year>2019</year>). <article-title>Machado-Joseph disease/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy</article-title>. <source>J. Neurochem.</source> <volume>148</volume>, <fpage>8</fpage>&#x2013;<lpage>28</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jnc.14541</pub-id>, <pub-id pub-id-type="pmid">29959858</pub-id></mixed-citation></ref>
<ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLoughlin</surname><given-names>H. S.</given-names></name> <name><surname>Moore</surname><given-names>L. R.</given-names></name> <name><surname>Chopra</surname><given-names>R.</given-names></name> <name><surname>Komlo</surname><given-names>R.</given-names></name> <name><surname>McKenzie</surname><given-names>M.</given-names></name> <name><surname>Blumenstein</surname><given-names>K. G.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice</article-title>. <source>Ann. Neurol.</source> <volume>84</volume>, <fpage>64</fpage>&#x2013;<lpage>77</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.25264</pub-id>, <pub-id pub-id-type="pmid">29908063</pub-id></mixed-citation></ref>
<ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLoughlin</surname><given-names>H. S.</given-names></name> <name><surname>Moore</surname><given-names>L. R.</given-names></name> <name><surname>Paulson</surname><given-names>H. L.</given-names></name></person-group> (<year>2020</year>). <article-title>Pathogenesis of SCA3 and implications for other polyglutamine diseases</article-title>. <source>Neurobiol. Dis.</source> <volume>134</volume>:<fpage>104635</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2019.104635</pub-id>, <pub-id pub-id-type="pmid">31669734</pub-id></mixed-citation></ref>
<ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mykowska</surname><given-names>A.</given-names></name> <name><surname>Sobczak</surname><given-names>K.</given-names></name> <name><surname>Wojciechowska</surname><given-names>M.</given-names></name> <name><surname>Kozlowski</surname><given-names>P.</given-names></name> <name><surname>Krzyzosiak</surname><given-names>W. J.</given-names></name></person-group> (<year>2011</year>). <article-title>CAG repeats mimic CUG repeats in the misregulation of alternative splicing</article-title>. <source>Nucleic Acids Res.</source> <volume>39</volume>, <fpage>8938</fpage>&#x2013;<lpage>8951</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nar/gkr608</pub-id>, <pub-id pub-id-type="pmid">21795378</pub-id></mixed-citation></ref>
<ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves-Carvalho</surname><given-names>A.</given-names></name> <name><surname>Logarinho</surname><given-names>E.</given-names></name> <name><surname>Freitas</surname><given-names>A.</given-names></name> <name><surname>Duarte-Silva</surname><given-names>S.</given-names></name> <name><surname>Costa</surname><given-names>M. d. C.</given-names></name> <name><surname>Silva-Fernandes</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2015</year>). <article-title>Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells</article-title>. <source>Hum. Mol. Genet.</source> <volume>24</volume>, <fpage>100</fpage>&#x2013;<lpage>117</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddu422</pub-id>, <pub-id pub-id-type="pmid">25143392</pub-id></mixed-citation></ref>
<ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olmos</surname><given-names>V.</given-names></name> <name><surname>Thompson</surname><given-names>E. N.</given-names></name> <name><surname>Gogia</surname><given-names>N.</given-names></name> <name><surname>Luttik</surname><given-names>K.</given-names></name> <name><surname>Veeranki</surname><given-names>V.</given-names></name> <name><surname>Ni</surname><given-names>L.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Dysregulation of alternative splicing in spinocerebellar ataxia type 1</article-title>. <source>Hum. Mol. Genet.</source> <volume>33</volume>, <fpage>138</fpage>&#x2013;<lpage>149</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddad170</pub-id>, <pub-id pub-id-type="pmid">37802886</pub-id></mixed-citation></ref>
<ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname><given-names>H. L.</given-names></name> <name><surname>Perez</surname><given-names>M. K.</given-names></name> <name><surname>Trottier</surname><given-names>Y.</given-names></name> <name><surname>Trojanowski</surname><given-names>J. Q.</given-names></name> <name><surname>Subramony</surname><given-names>S. H.</given-names></name> <name><surname>Das</surname><given-names>S. S.</given-names></name> <etal/></person-group>. (<year>1997</year>). <article-title>Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3</article-title>. <source>Neuron</source> <volume>19</volume>, <fpage>333</fpage>&#x2013;<lpage>344</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0896-6273(00)80943-5</pub-id></mixed-citation></ref>
<ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulson</surname><given-names>H. L.</given-names></name> <name><surname>Shakkottai</surname><given-names>V. G.</given-names></name> <name><surname>Clark</surname><given-names>H. B.</given-names></name> <name><surname>Orr</surname><given-names>H. T.</given-names></name></person-group> (<year>2017</year>). <article-title>Polyglutamine spinocerebellar ataxias &#x2014; from genes to potential treatments</article-title>. <source>Nat. Rev. Neurosci.</source> <volume>18</volume>, <fpage>613</fpage>&#x2013;<lpage>626</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrn.2017.92</pub-id>, <pub-id pub-id-type="pmid">28855740</pub-id></mixed-citation></ref>
<ref id="ref36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedroso</surname><given-names>J. L.</given-names></name> <name><surname>Pinto</surname><given-names>W. B. V. de R.</given-names></name> <name><surname>de Souza</surname><given-names>P. V. S.</given-names><prefix>de</prefix></name> <name><surname>Andriotti</surname><given-names>C.</given-names></name> <name><surname>Stavale</surname><given-names>J. N.</given-names></name> <name><surname>Barsottini</surname><given-names>O. G. P.</given-names></name></person-group> (<year>2016</year>) <article-title>Anterior horn degeneration in Machado-Joseph disease</article-title> <source>J. Neurol. Sci.</source> <volume>368</volume>, <fpage>290</fpage>&#x2013;<lpage>291</lpage> doi: <pub-id pub-id-type="doi">10.1016/j.jns.2016.07.037</pub-id></mixed-citation></ref>
<ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>S.</given-names></name> <name><surname>De Carvalho</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Machado-Joseph disease presenting as motor neuron disease</article-title>. <source>Amyotroph. Lateral Scler.</source> <volume>9</volume>, <fpage>188</fpage>&#x2013;<lpage>191</lpage>. doi: <pub-id pub-id-type="doi">10.1080/17482960701702603</pub-id></mixed-citation></ref>
<ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putka</surname><given-names>A. F.</given-names></name> <name><surname>Mohanty</surname><given-names>V.</given-names></name> <name><surname>Cologna</surname><given-names>S. M.</given-names></name> <name><surname>McLoughlin</surname><given-names>H. S.</given-names></name></person-group> (<year>2025</year>). <article-title>Cerebellar lipid dysregulation in SCA3: a comparative study in patients and mice</article-title>. <source>Neurobiol. Dis.</source> <volume>206</volume>:<fpage>106827</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.nbd.2025.106827</pub-id>, <pub-id pub-id-type="pmid">39900303</pub-id></mixed-citation></ref>
<ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramani</surname><given-names>B.</given-names></name> <name><surname>Panwar</surname><given-names>B.</given-names></name> <name><surname>Moore</surname><given-names>L. R.</given-names></name> <name><surname>Wang</surname><given-names>B.</given-names></name> <name><surname>Huang</surname><given-names>R.</given-names></name> <name><surname>Guan</surname><given-names>Y.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes</article-title>. <source>Hum. Mol. Genet.</source> <volume>26</volume>, <fpage>3362</fpage>&#x2013;<lpage>3374</lpage>. doi: <pub-id pub-id-type="doi">10.1093/hmg/ddx224</pub-id>, <pub-id pub-id-type="pmid">28854700</pub-id></mixed-citation></ref>
<ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reina</surname><given-names>C. P.</given-names></name> <name><surname>Nabet</surname><given-names>B. Y.</given-names></name> <name><surname>Young</surname><given-names>P. D.</given-names></name> <name><surname>Pittman</surname><given-names>R. N.</given-names></name></person-group> (<year>2012</year>). <article-title>Basal and stress-induced Hsp70 are modulated by ataxin-3</article-title>. <source>Cell Stress Chaperones</source> <volume>17</volume>, <fpage>729</fpage>&#x2013;<lpage>742</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12192-012-0346-2</pub-id>, <pub-id pub-id-type="pmid">22777893</pub-id></mixed-citation></ref>
<ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>T. J. R.</given-names></name> <name><surname>Adanyaguh</surname><given-names>I.</given-names></name> <name><surname>Barsottini</surname><given-names>O. G. P.</given-names></name> <name><surname>Bender</surname><given-names>B.</given-names></name> <name><surname>Cendes</surname><given-names>F.</given-names></name> <name><surname>Coutinho</surname><given-names>L.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>Genotype-specific spinal cord damage in spinocerebellar ataxias: an ENIGMA-Ataxia study</article-title>. <source>J. Neurol. Neurosurg. Psychiatry</source> <volume>95</volume>, <fpage>682</fpage>&#x2013;<lpage>690</lpage>. doi: <pub-id pub-id-type="doi">10.1136/jnnp-2023-332696</pub-id>, <pub-id pub-id-type="pmid">38383154</pub-id></mixed-citation></ref>
<ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rezende</surname><given-names>T. J. R.</given-names></name> <name><surname>de Paiva</surname><given-names>J. L. R.</given-names></name> <name><surname>Martinez</surname><given-names>A. R. M.</given-names></name> <name><surname>Lopes-Cendes</surname><given-names>I.</given-names></name> <name><surname>Pedroso</surname><given-names>J. L.</given-names></name> <name><surname>Barsottini</surname><given-names>O. G. P.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Structural signature of SCA3: from presymptomatic to late disease stages</article-title>. <source>Ann. Neurol.</source> <volume>84</volume>, <fpage>401</fpage>&#x2013;<lpage>408</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ana.25297</pub-id>, <pub-id pub-id-type="pmid">30014526</pub-id></mixed-citation></ref>
<ref id="ref43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richner</surname><given-names>M.</given-names></name> <name><surname>Jager</surname><given-names>S. B.</given-names></name> <name><surname>Siupka</surname><given-names>P.</given-names></name> <name><surname>Vaegter</surname><given-names>C. B.</given-names></name></person-group> (<year>2017</year>). <article-title>Hydraulic extrusion of the spinal cord and isolation of dorsal root ganglia in rodents</article-title>. <source>J. Vis. Exp.</source> <volume>119</volume>:<fpage>55226</fpage>. doi: <pub-id pub-id-type="doi">10.3791/55226</pub-id>, <pub-id pub-id-type="pmid">28190031</pub-id></mixed-citation></ref>
<ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roda</surname><given-names>R. H.</given-names></name> <name><surname>FitzGibbon</surname><given-names>E. J.</given-names></name> <name><surname>Boucekkine</surname><given-names>H.</given-names></name> <name><surname>Schindler</surname><given-names>A. B.</given-names></name> <name><surname>Blackstone</surname><given-names>C.</given-names></name></person-group> (<year>2016</year>). <article-title>Neurologic syndrome associated with homozygous mutation at MAG sialic acid binding site</article-title>. <source>Ann. Clin. Transl. Neurol.</source> <volume>3</volume>, <fpage>650</fpage>&#x2013;<lpage>654</lpage>. doi: <pub-id pub-id-type="doi">10.1002/acn3.329</pub-id>, <pub-id pub-id-type="pmid">27606346</pub-id></mixed-citation></ref>
<ref id="ref45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x00FC;b</surname><given-names>U.</given-names></name> <name><surname>de Vos</surname><given-names>R. A. I.</given-names></name> <name><surname>Brunt</surname><given-names>E. R.</given-names></name> <name><surname>Schultz</surname><given-names>C.</given-names></name> <name><surname>Paulson</surname><given-names>H.</given-names></name> <name><surname>Del Tredici</surname><given-names>K.</given-names></name> <etal/></person-group>. (<year>2002a</year>). <article-title>Degeneration of the external cuneate nucleus in spinocerebellar ataxia type 3 (Machado&#x2013;Joseph disease)</article-title>. <source>Brain Res.</source> <volume>953</volume>, <fpage>126</fpage>&#x2013;<lpage>134</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0006-8993(02)03278-X</pub-id></mixed-citation></ref>
<ref id="ref46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x00FC;b</surname><given-names>U.</given-names></name> <name><surname>de Vos</surname><given-names>R. A. I.</given-names></name> <name><surname>Schultz</surname><given-names>C.</given-names></name> <name><surname>Brunt</surname><given-names>E. R.</given-names></name> <name><surname>Paulson</surname><given-names>H.</given-names></name> <name><surname>Braak</surname><given-names>H.</given-names></name></person-group> (<year>2002b</year>). <article-title>Spinocerebellar ataxia type 3 (Machado&#x2013;Joseph disease): severe destruction of the lateral reticular nucleus</article-title>. <source>Brain</source> <volume>125</volume>, <fpage>2115</fpage>&#x2013;<lpage>2124</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awf208</pub-id></mixed-citation></ref>
<ref id="ref47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russ</surname><given-names>D. E.</given-names></name> <name><surname>Cross</surname><given-names>R. B. P.</given-names></name> <name><surname>Li</surname><given-names>L.</given-names></name> <name><surname>Koch</surname><given-names>S. C.</given-names></name> <name><surname>Matson</surname><given-names>K. J. E.</given-names></name> <name><surname>Yadav</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>A harmonized atlas of mouse spinal cord cell types and their spatial organization</article-title>. <source>Nat. Commun.</source> <volume>12</volume>:<fpage>5722</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-021-25125-1</pub-id>, <pub-id pub-id-type="pmid">34588430</pub-id></mixed-citation></ref>
<ref id="ref48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>M.</given-names></name> <name><surname>Dam&#x00E1;sio</surname><given-names>J.</given-names></name> <name><surname>Kun-Rodrigues</surname><given-names>C.</given-names></name> <name><surname>Barbot</surname><given-names>C.</given-names></name> <name><surname>Sequeiros</surname><given-names>J.</given-names></name> <name><surname>Br&#x00E1;s</surname><given-names>J.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Novel MAG variant causes cerebellar Ataxia with oculomotor apraxia: molecular basis and expanded clinical phenotype</article-title>. <source>J. Clin. Med.</source> <volume>9</volume>:<fpage>1212</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jcm9041212</pub-id>, <pub-id pub-id-type="pmid">32340215</pub-id></mixed-citation></ref>
<ref id="ref49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saute</surname><given-names>J. A. M.</given-names></name> <name><surname>Jardim</surname><given-names>L. B.</given-names></name></person-group> (<year>2015</year>). <article-title>Machado Joseph disease: clinical and genetic aspects, and current treatment</article-title>. <source>Expert Opin. Orphan Drugs</source> <volume>3</volume>, <fpage>517</fpage>&#x2013;<lpage>535</lpage>. doi: <pub-id pub-id-type="doi">10.1517/21678707.2015.1025747</pub-id></mixed-citation></ref>
<ref id="ref50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherzed</surname><given-names>W.</given-names></name> <name><surname>Brunt</surname><given-names>E. R.</given-names></name> <name><surname>Heinsen</surname><given-names>H.</given-names></name> <name><surname>de Vos</surname><given-names>R. A.</given-names></name> <name><surname>Seidel</surname><given-names>K.</given-names></name> <name><surname>B&#x00FC;rk</surname><given-names>K.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Pathoanatomy of cerebellar degeneration in spinocerebellar Ataxia type 2 (SCA2) and type 3 (SCA3)</article-title>. <source>Cerebellum</source> <volume>11</volume>, <fpage>749</fpage>&#x2013;<lpage>760</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12311-011-0340-8</pub-id>, <pub-id pub-id-type="pmid">22198871</pub-id></mixed-citation></ref>
<ref id="ref51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schilling</surname><given-names>J.</given-names></name> <name><surname>Broemer</surname><given-names>M.</given-names></name> <name><surname>Atanassov</surname><given-names>I.</given-names></name> <name><surname>Duernberger</surname><given-names>Y.</given-names></name> <name><surname>Vorberg</surname><given-names>I.</given-names></name> <name><surname>Dieterich</surname><given-names>C.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Deregulated splicing is a major mechanism of RNA-induced toxicity in Huntington&#x2019;s disease</article-title>. <source>J. Mol. Biol.</source> <volume>431</volume>, <fpage>1869</fpage>&#x2013;<lpage>1877</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jmb.2019.01.034</pub-id>, <pub-id pub-id-type="pmid">30711541</pub-id></mixed-citation></ref>
<ref id="ref52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>I.</given-names></name> <name><surname>Linden</surname><given-names>M.</given-names></name> <name><surname>Khazneh</surname><given-names>H.</given-names></name> <name><surname>Evert</surname><given-names>B. O.</given-names></name> <name><surname>Breuer</surname><given-names>P.</given-names></name> <name><surname>Klockgether</surname><given-names>T.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>362</volume>, <fpage>734</fpage>&#x2013;<lpage>739</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2007.08.062</pub-id>, <pub-id pub-id-type="pmid">17764659</pub-id></mixed-citation></ref>
<ref id="ref53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>K. H.</given-names></name> <name><surname>DiFranco</surname><given-names>D. M.</given-names></name> <name><surname>Putka</surname><given-names>A. F.</given-names></name> <name><surname>Mato</surname><given-names>J. P.</given-names></name> <name><surname>Jarrah</surname><given-names>S. I.</given-names></name> <name><surname>Stec</surname><given-names>N. R.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Disease-associated oligodendrocyte signatures are spatiotemporally dysregulated in spinocerebellar ataxia type 3</article-title>. <source>Front. Neurosci.</source> <volume>17</volume>: <fpage>1118429</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2023.1118429</pub-id>, <pub-id pub-id-type="pmid">36875652</pub-id></mixed-citation></ref>
<ref id="ref54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>K. H.</given-names></name> <name><surname>Putka</surname><given-names>A. F.</given-names></name> <name><surname>McLoughlin</surname><given-names>H. S.</given-names></name></person-group> (<year>2022a</year>). <article-title>Pathogenetic mechanisms underlying spinocerebellar ataxia type 3 are altered in primary oligodendrocyte culture</article-title>. <source>Cells</source> <volume>11</volume>:<fpage>2615</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells11162615</pub-id>, <pub-id pub-id-type="pmid">36010688</pub-id></mixed-citation></ref>
<ref id="ref55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>K. H.</given-names></name> <name><surname>Zalon</surname><given-names>A. J.</given-names></name> <name><surname>DiFranco</surname><given-names>D. M.</given-names></name> <name><surname>Putka</surname><given-names>A. F.</given-names></name> <name><surname>Stec</surname><given-names>N. R.</given-names></name> <name><surname>Jarrah</surname><given-names>S. I.</given-names></name> <etal/></person-group>. (<year>2024</year>). <article-title>ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice</article-title>. <source>Mol. Ther.</source> <volume>32</volume>, <fpage>1359</fpage>&#x2013;<lpage>1372</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ymthe.2024.02.033</pub-id>, <pub-id pub-id-type="pmid">38429929</pub-id></mixed-citation></ref>
<ref id="ref56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuster</surname><given-names>K. H.</given-names></name> <name><surname>Zalon</surname><given-names>A. J.</given-names></name> <name><surname>Zhang</surname><given-names>H.</given-names></name> <name><surname>DiFranco</surname><given-names>D. M.</given-names></name> <name><surname>Stec</surname><given-names>N. R.</given-names></name> <name><surname>Haque</surname><given-names>Z.</given-names></name> <etal/></person-group>. (<year>2022b</year>). <article-title>Impaired oligodendrocyte maturation is an early feature in SCA3 disease pathogenesis</article-title>. <source>J. Neurosci.</source> <volume>42</volume>, <fpage>1604</fpage>&#x2013;<lpage>1617</lpage>. doi: <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1954-20.2021</pub-id>, <pub-id pub-id-type="pmid">35042771</pub-id></mixed-citation></ref>
<ref id="ref57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shorrock</surname><given-names>H. K.</given-names></name> <name><surname>Lennon</surname><given-names>C. D.</given-names></name> <name><surname>Aliyeva</surname><given-names>A.</given-names></name> <name><surname>Davey</surname><given-names>E. E.</given-names></name> <name><surname>DeMeo</surname><given-names>C. C.</given-names></name> <name><surname>Pritchard</surname><given-names>C. E.</given-names></name> <etal/></person-group>. (<year>2023</year>). <article-title>Widespread alternative splicing dysregulation occurs presymptomatically in CAG expansion spinocerebellar ataxias</article-title>. <source>Brain</source> <volume>147</volume>, <fpage>486</fpage>&#x2013;<lpage>504</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awad329</pub-id>, <pub-id pub-id-type="pmid">37776516</pub-id></mixed-citation></ref>
<ref id="ref58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>F.</given-names></name> <name><surname>Evert</surname><given-names>B. O.</given-names></name> <name><surname>Han</surname><given-names>X.</given-names></name> <name><surname>Breuer</surname><given-names>P.</given-names></name> <name><surname>W&#x00FC;llner</surname><given-names>U.</given-names></name></person-group> (<year>2024</year>). <article-title>Spinocerebellar Ataxia type 3 pathophysiology&#x2014;implications for translational research and clinical studies</article-title>. <source>Int. J. Mol. Sci.</source> <volume>25</volume>:<fpage>3984</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25073984</pub-id>, <pub-id pub-id-type="pmid">38612794</pub-id></mixed-citation></ref>
<ref id="ref59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suga</surname><given-names>N.</given-names></name> <name><surname>Katsuno</surname><given-names>M.</given-names></name> <name><surname>Koike</surname><given-names>H.</given-names></name> <name><surname>Banno</surname><given-names>H.</given-names></name> <name><surname>Suzuki</surname><given-names>K.</given-names></name> <name><surname>Hashizume</surname><given-names>A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Schwann cell involvement in the peripheral neuropathy of spinocerebellar ataxia type 3</article-title>. <source>Neuropathol. Appl. Neurobiol.</source> <volume>40</volume>, <fpage>628</fpage>&#x2013;<lpage>639</lpage>. doi: <pub-id pub-id-type="doi">10.1111/nan.12055</pub-id>, <pub-id pub-id-type="pmid">23617879</pub-id></mixed-citation></ref>
<ref id="ref60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>N.</given-names></name> <name><surname>Chen</surname><given-names>Z.</given-names></name> <name><surname>Wan</surname><given-names>L.</given-names></name> <name><surname>Tang</surname><given-names>B.</given-names></name> <name><surname>Jiang</surname><given-names>H.</given-names></name></person-group> (<year>2020</year>). <article-title>MR imaging of SCA3/MJD</article-title>. <source>Front. Neurosci.</source> <volume>14</volume>:<fpage>749</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnins.2020.00749</pub-id>, <pub-id pub-id-type="pmid">32848545</pub-id></mixed-citation></ref>
<ref id="ref61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>M.</given-names></name> <name><surname>Abe</surname><given-names>K.</given-names></name> <name><surname>Aoki</surname><given-names>M.</given-names></name> <name><surname>Kameya</surname><given-names>T.</given-names></name> <name><surname>Kaneko</surname><given-names>J.</given-names></name> <name><surname>Shoji</surname><given-names>M.</given-names></name> <etal/></person-group>. (<year>1996</year>). <article-title>Analysis of CAG trinucleotide expansion associated with Machado-Joseph disease</article-title>. <source>J. Neurol. Sci.</source> <volume>136</volume>, <fpage>101</fpage>&#x2013;<lpage>107</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0022-510X(95)00307-N</pub-id></mixed-citation></ref>
<ref id="ref62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiatr</surname><given-names>K.</given-names></name> <name><surname>Marczak</surname><given-names>&#x0141;.</given-names></name> <name><surname>P&#x00E9;rot</surname><given-names>J.-B.</given-names></name> <name><surname>Brouillet</surname><given-names>E.</given-names></name> <name><surname>Flament</surname><given-names>J.</given-names></name> <name><surname>Figiel</surname><given-names>M.</given-names></name></person-group> (<year>2021</year>). <article-title>Broad influence of mutant Ataxin-3 on the proteome of the adult brain, Young neurons, and axons reveals central molecular processes and biomarkers in SCA3/MJD using Knock-in mouse model</article-title>. <source>Front. Mol. Neurosci.</source> <volume>14</volume>:<fpage>658339</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2021.658339</pub-id>, <pub-id pub-id-type="pmid">34220448</pub-id></mixed-citation></ref>
<ref id="ref63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiatr</surname><given-names>K.</given-names></name> <name><surname>Piasecki</surname><given-names>P.</given-names></name> <name><surname>Marczak</surname><given-names>&#x0141;.</given-names></name> <name><surname>Wojciechowski</surname><given-names>P.</given-names></name> <name><surname>Kurkowiak</surname><given-names>M.</given-names></name> <name><surname>P&#x0142;oski</surname><given-names>R.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>Altered levels of proteins and phosphoproteins, in the absence of early causative transcriptional changes, shape the molecular pathogenesis in the brain of Young Presymptomatic Ki91 SCA3/MJD mouse</article-title>. <source>Mol. Neurobiol.</source> <volume>56</volume>, <fpage>8168</fpage>&#x2013;<lpage>8202</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12035-019-01643-4</pub-id>, <pub-id pub-id-type="pmid">31201651</pub-id></mixed-citation></ref>
<ref id="ref64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J. I.</given-names></name> <name><surname>Reed</surname><given-names>R. B.</given-names></name> <name><surname>Grabowski</surname><given-names>P. J.</given-names></name> <name><surname>Artzt</surname><given-names>K.</given-names></name></person-group> (<year>2002</year>). <article-title>Function of quaking in myelination: regulation of alternative splicing</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>99</volume>, <fpage>4233</fpage>&#x2013;<lpage>4238</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.072090399</pub-id>, <pub-id pub-id-type="pmid">11917126</pub-id></mixed-citation></ref>
<ref id="ref65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Z.-X.</given-names></name> <name><surname>Chen</surname><given-names>X.-Y.</given-names></name> <name><surname>Li</surname><given-names>M.-C.</given-names></name> <name><surname>Chen</surname><given-names>X.-Y.</given-names></name> <name><surname>Qiu</surname><given-names>Y.-S.</given-names></name> <name><surname>Yuan</surname><given-names>R.-Y.</given-names></name> <etal/></person-group>. (<year>2025</year>). <article-title>Associations between CAG repeat size, brain and spinal cord volume loss, and motor symptoms in spinocerebellar ataxia type 3: a cohort study</article-title>. <source>Orphanet J. Rare Dis.</source> <volume>20</volume>:<fpage>35</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s13023-025-03531-8</pub-id>, <pub-id pub-id-type="pmid">39849568</pub-id></mixed-citation></ref>
<ref id="ref66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuelling</surname><given-names>L. W.</given-names></name> <name><surname>Waggener</surname><given-names>C. T.</given-names></name> <name><surname>Afshari</surname><given-names>F. S.</given-names></name> <name><surname>Lister</surname><given-names>J. A.</given-names></name> <name><surname>Fuss</surname><given-names>B.</given-names></name></person-group> (<year>2012</year>). <article-title>Autotaxin/ENPP2 regulates oligodendrocyte differentiation in vivo in the developing zebrafish hindbrain</article-title>. <source>Glia</source> <volume>60</volume>, <fpage>1605</fpage>&#x2013;<lpage>1618</lpage>. doi: <pub-id pub-id-type="doi">10.1002/glia.22381</pub-id>, <pub-id pub-id-type="pmid">22821873</pub-id></mixed-citation></ref>
<ref id="ref67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zech</surname><given-names>M.</given-names></name> <name><surname>Brunet</surname><given-names>T.</given-names></name> <name><surname>&#x0160;korv&#x00E1;nek</surname><given-names>M.</given-names></name> <name><surname>Blaschek</surname><given-names>A.</given-names></name> <name><surname>Vill</surname><given-names>K.</given-names></name> <name><surname>Hanker</surname><given-names>B.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Recessive null-allele variants in MAG associated with spastic ataxia, nystagmus, neuropathy, and dystonia</article-title>. <source>Parkinsonism Relat. Disord.</source> <volume>77</volume>, <fpage>70</fpage>&#x2013;<lpage>75</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.parkreldis.2020.06.027</pub-id>, <pub-id pub-id-type="pmid">32629324</pub-id></mixed-citation></ref>
<ref id="ref68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>L.</given-names></name> <name><surname>Zhang</surname><given-names>D.</given-names></name> <name><surname>McLoughlin</surname><given-names>H. S.</given-names></name> <name><surname>Zalon</surname><given-names>A. J.</given-names></name> <name><surname>Aravind</surname><given-names>L.</given-names></name> <name><surname>Paulson</surname><given-names>H. L.</given-names></name></person-group> (<year>2018</year>). <article-title>Loss of the spinocerebellar ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways</article-title>. <source>PLoS One</source> <volume>13</volume>:<fpage>e0204438</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0204438</pub-id>, <pub-id pub-id-type="pmid">30231063</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2153463/overview">Hongjian Pu</ext-link>, University of Pittsburgh, United States</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3220928/overview">Haoli Wang</ext-link>, Massachusetts Institute of Technology, United States</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/465002/overview">Patr&#x00ED;cia Maciel</ext-link>, University of Minho, Portugal</p>
</fn>
</fn-group>
</back>
</article>